Home › Overweight › Iowa
Overweight clinical trials in Iowa
9 studies for Overweight are looking for participants at sites in Iowa.
Cities in Iowa
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
- Iowa Diabetes and Endocrinology Research Center, West Des Moines
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07794579A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- Iowa Diabetes and Endocrinology Research Center, West Des Moines
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07392190A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- Iowa Diabetes and Endocrinology Research Center, West Des Moines
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07321886Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- McFarland Clinic PC, Ames
- Midwest Cardiovascular Research Foundation, Davenport
RecruitingPhase 3
Ages 45 to 99 · All sexes · Updated Sep 22, 2026 · NCT07037433A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Des Moines
- ACCOMPLISH-2 Research Site, Iowa City
RecruitingPhase 3Healthy volunteers welcome
Ages 18 to 79 · All sexes · Updated Sep 11, 2026 · NCT07654374A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Iowa Diabetes and Endocrinology Research Center, West Des Moines
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 8, 2026 · NCT06143956Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
- Iowa Diabetes Research, West Des Moines
RecruitingPhase 3
Ages 18 to 99 · All sexes · Updated Sep 3, 2026 · NCT07684144A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Ames
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT07784725Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Iowa City
RecruitingPhase 3
Ages 18 to 79 · All sexes · Updated Aug 10, 2026 · NCT07654361From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.